A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adenoassociated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults with Hemophilia B
|Effective start/end date||5/30/12 → 5/30/17|
- ASKLEPIOS Biopharmaceutical, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.